1646-5830

S1646-58302021000300301

Portugal

30 09 2021

15 3 301 307

2021 1

1-7

2013

2007 86 3 3

315-9

2007 197 5 5

480.e1-5

2008 87 7 7

745-50

2009 200 1 1

35.e1-6

2011 204 4 4

283-7

2012 207 6 6

439-40

2003 110 ^s20 ^s20 20

46-51

1984 150 3 3

225-8

Novartis 2009 6

1-10

1960 3

386-408

1992 166

1260-1

2007 114 3 3

343-8

2015 43 6 6

703-6

2006 108

1499-505

2007 196 4 4

313.e1-6

2008 199 1 1

34.e1-5

2013 209 1 1

e6-7

2013 209 1 1

32.e1-6

Institute for Safe Medication Practices 2020 2020

2017 46 6 6

509-21

2012 52 2 2

173-8

2019

2015 213

382.e1

2013 170 1 1

25-32

2007

197:495.e1-5

2010 117

1358-65

1957 64

113-8

ACOG practice bulletin No 205

2019 133 2 2

e110-27

1991 77

465-70

2002 100

946-50

2012 41 8 8

753-71

ACOG Practice Bulletin No 107

2009 114 2 2

386-97

Jessica Dy et al 2013 35 9 9

840-57

FIGO Intrapartum Fetal Monitoring Expert Consensus Panel 2015 131 1 1

13-24

1995 102 8 8

644-7

1994 101 1 1

44-8

FIGO Intrapartum Fetal Monitoring Expert Consensus Panel 2015 131 1 1

5-8

1996 103

306-12

WHO 2014

2017 46 6 6

489-97

2017 46 6 6

479-87

2013 23 6 6

2018 20 8 8

1988 71 2 2

147-9

1991 78 2 2

227-30

1993 82 6 6

1009-12

1999 94 3 3

455-63

2009 201 3 3

2010 203 4 4

296-304

2011 118 2, Part 1 2, Part 1

249-56

2013 120 11 11

1403-12

2013 13 7 7

2014 9 10 10

Norwegian Guidelines 2014 25

1-3

NICE Guideline 190

2014 28

1-839

Society of Obstetricians and Gynaecologists of Canada

2013 35 9 9

2007 197 5 5

445-6

2008 198 6 6

622.e1-7

2017 46 6 6

539-43